Hyderabad-based vaccine maker Bharat Biotech on Tuesday stated the present provide price of its Covid-19 vaccine Covaxin to the Centre isn’t sustainable in the long term.
Covaxin is being provided to the Centre at a price of Rs 150 per dose.
The low provide worth for the Centre is leading to the next pricing construction for the non-public sector, the corporate stated.
“The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech stated in a press release.
Various components akin to low procurement volumes, excessive distribution prices and different enterprise causes are answerable for the present worth of Covaxin, the corporate stated whereas justifying the upper worth of its vaccine when in comparison with different Covid-19 vaccines obtainable for the non-public sector in India.
Bharat Biotech has up to now invested over Rs 500 crores in danger from its personal assets for product improvement, scientific trials and establishing of producing amenities for Covaxin, it added.
At the second three Covid-19 vaccines have been granted emergency use approval in India. They are Bharat Biotech’s Covaxin, Serum Institute of India’s Covishield and Russia’s Sputnik V.
(With PTI inputs)